Active Ingredient History
Labetalol is a blocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive. It may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. The capacity of labetalol HCl to block alpha receptors in man has been demonstrated by attenuation of the pressor effect of phenylephrine and by a significant reduction of the pressor response caused by immersing the hand in ice-cold water ("cold-pressor test"). Labetalol HCl's beta1-receptor blockade in man was demonstrated by a small decrease in the resting heart rate, attenuation of tachycardia produced by isoproterenol or exercise, and by attenuation of the reflex tachycardia to the hypotension produced by amyl nitrite. Beta2-receptor blockade was demonstrated by inhibition of the isoproterenol-induced fall in diastolic blood pressure. Both the alpha- and beta-blocking actions of orally administered labetalol HCl contribute to a decrease in blood pressure in hypertensive patients. Labetalol HCl consistently, in dose-related fashion, blunted increases in exercise-induced blood pressure and heart rate, and in their double product. The pulmonary circulation during exercise was not affected by labetalol HCl dosing. Single oral doses of labetalol HCl administered to patients with coronary artery disease had no significant effect on sinus rate, intraventricular conduction, or QRS duration. The atrioventricular (A-V) conduction time was modestly prolonged in two of seven patients. In another study, IV labetalol HCl slightly prolonged A-V nodal conduction time and atrial effective refractory period with only small changes in heart rate. The metabolism of labetalol is mainly through conjugation to glucuronide metabolites. These metabolites are present in plasma and are excreted in the urine and, via the bile, into the feces. Approximately 55% to 60% of a dose appears in the urine as conjugates or unchanged labetalol within the first 24 hours of dosing. Labetalol has been shown to cross the placental barrier in humans. Only negligible amounts of the drug crossed the blood-brain barrier in animal studies. Labetalol is approximately 50% protein bound. Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol HCl from the general circulation. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypertension (approved 1988)
Acute Coronary Syndrome (Early Phase 1)
Anesthesia (Phase 4)
Anterior Cruciate Ligament Injuries (Phase 4)
Arterial Occlusive Diseases (Phase 2)
Arthroscopy (Phase 4)
Bacterial Infections (Phase 4)
Blood Loss, Surgical (Phase 4)
Blood Pressure (Phase 2)
Bronchoscopy (Phase 4)
Cerebral Hemorrhage (Phase 2)
Cocaine-Related Disorders (Phase 2)
Craniotomy (Phase 1/Phase 2)
Drug-Related Side Effects and Adverse Reactions (Phase 2/Phase 3)
General Surgery (Phase 4)
Glioblastoma (Phase 1/Phase 2)
Heart Rate (Phase 2)
Hypertension (Phase 4)
Hypertension, Pregnancy-Induced (Phase 4)
Hypotension (Phase 4)
Ischemic Stroke (Phase 4)
Laparoscopy (Phase 4)
Obesity, Morbid (Early Phase 1)
Orthognathic Surgery (Phase 4)
Pain, Postoperative (Phase 1/Phase 2)
Perfusion (Phase 4)
Pheochromocytoma (Phase 2)
Postoperative Hemorrhage (Phase 4)
Pre-Eclampsia (Phase 4)
Proteinuria (Phase 1/Phase 2)
Sinusitis (Phase 2)
Stroke (Phase 2)
Thrombosis (Phase 2)
Tobacco Use Disorder (Phase 2)
Tuberculosis (Phase 4)
Vascular Diseases (Phase 2)
Vertigo (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
